权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

ヒト胚細胞性腫瘍の分化関連糖鎖抗原の免疫学的並びに生化学的研究と臨床診断への応用

人类生殖细胞肿瘤分化相关糖抗原的免疫生化研究及其在临床诊断中的应用

基本信息

批准号：
59570699
负责人：
SEKIYA Souei
金额：
$ 1.02万
依托单位：
Chiba University
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1984
资助国家：
日本
起止时间：
1984 至 1986
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-59570699/
关键词：
Germcell tumor Glycopeptide lectin Carbohydrate antigen 分化抗原

项目摘要

Human antibody against an embryoglycan present on a mouse teratocarcinoma cell line F9 was found in sera from 16 out of 29 patients with embryonal carcinoma, yolk sac tumor, immature teratoma, and choriocarcinoma of gonadal and extragonadal origins by Farr assay. In contrast, none of sera from patients (77 cases) with dysgerminoma, seminoma, germinoma, and mature teratoma, or patients (118 cases) with non-germ cell types of ovarian tumors contained this antibody. The antigenic embryoglycan was of high molecular weight (more than 70,000) on Sephacryl S300 column chromatography, and carried binding sites for Grifonia simplicifolia agglutinin-1. The antigenic embryoglycan was also found in F9 cell-cultured medium. Absorption of patients' sera with synthetic blood group B trisaccharides failed to remove the antibody against F9 embryoglycan. None of these patients' sera showed higher hemaggulutination titer to rabbit erythrocytes than the normal range. In contrast, <alpha> -galactosyl carbohydrates obtained from Ehrlich ascites tumor cell effectively inhibited the binding of patients' sera with F9 embryoglycan. These results indicate that the human antibody against F9 embryoglycan recognizes <alpha> -galactosyl structures, that are distinct from B blood group antigen, but are cross-reactive with <alpha> -galactosyl structures on Ehrlich ascites cells.

通过Farr法检测，在29例胚胎癌、卵黄囊瘤、未成熟畸胎瘤和性腺及性腺外起源的绒毛膜癌患者中，有16例血清中发现了抗小鼠畸胎瘤细胞系F9上存在的胚胎多糖的人抗体。与此相反，无生殖细胞瘤、卵巢上皮瘤、生殖细胞瘤和成熟畸胎瘤患者（77例）或非生殖细胞型卵巢肿瘤患者（118例）的血清均不含该抗体。经Sephacryl S300柱层析鉴定，该抗原性胚胎多糖分子量较大（大于70，000），并带有与Grifonia simplicifolia agglutinin-1结合的位点。在F9细胞培养液中也发现了抗原性的胚胎多糖。用合成血型B三聚氰胺吸收患者血清不能去除抗F9胚胎聚糖的抗体。这些患者的血清均未显示高于正常范围的兔红细胞血凝素滴度。相反，<alpha>从埃利希腹水瘤细胞中获得的β-半乳糖基碳水化合物有效地抑制患者血清与F9胚胎聚糖的结合。这些结果表明，抗F9胚胎聚糖的人抗体识别<alpha>与B血型抗原不同的β-半乳糖基结构，但<alpha>与埃利希腹水细胞上的β-半乳糖基结构交叉反应。